PRECIGEN, INC. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Precigen achieved Q2 2026 net income of $20.1M ($0.06/share basic) on PAPZIMEOS product revenues of $53.1M, more than double Q1 2026. The company reached cash flow profitability milestone with 500+ patients enrolled in patient hub, 7-year FDA market exclusivity, permanent J-code (J3404), and payer coverage across ~315M US lives (~100% insured). Cash position of $38.7M (cash, equivalents, investments) is expected to support cash flow break-even by end of 2026.
Why this rating
Significant milestone: company achieved profitability ($20.1M net income) on FDA-approved commercial product with broad payer coverage. $53.1M quarterly revenue (24% of $219M market cap) demonstrates real commercial traction. Strong cash position enables runway. However, sustainability depends on PAPZIMEOS revenue growth continuation in niche RRP indication.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.